Auxilium Pharmaceuticals, Inc.

  • Huge Potential For First Line Therapy For Frozen Shoulder

    By Kanak Kanti - July 17, 2013 | Tickers: ABBV, AUXL, HALO

    Editor's Note: This article has been amended to better describe Auxilium's drugs and pipeline prospects. Motley Fool apologizes for the inaccuracies.

    Xiaflex from Auxilium Pharmaceuticals (NASDAQ: AUXL) is used to treat Dupuytren’s contracture. The drug recently increased its revenue potential after announcing a positive outcome for the treatment of Frozen Shoulder Syndrome (FSS), a related disease that affects one in 20 adults worldwide. If approved, Xiaflex will more »

  • Identifying the Biggest Gem in Antares's Pipeline

    By Ali Yasar - June 13, 2013 | Tickers: ABT, ATRS, AUXL

    Following the publication of my article on the blockbuster potential of Antares Pharma's (NASDAQ: ATRS) transformational product (Otrexup), I have been inundated with reader requests to conduct a valuation study on another drug-device combination currently being advanced into clinic by Antares, i.e., Vibex QS-T, which is targeting the testosterone replacement therapy (TRT) market. 

    QS-T is being developed to administer testosterone using a subcutaneous (SC) injection route by patients more »

  • Sell in May, But Don't Go Away

    By Declan Fallon - May 8, 2013 | Tickers: AUXL, KKD, MDSO, THC, TSO, TFM

    The most recent high for the S&P qualified the market under a 'sell' criteria for my Investing Strategy. The last time this happened was in March-April 2012, when the index went on to shed nearly 11% from peak-to-trough by the time the market bottomed in June 2012. However, this should not be viewed as a clarion call to sell everything, but may instead offer a better opportunity to generate more »

  • 3 Healthcare Stocks to Avoid

    By Mohsin Saeed - May 2, 2013 | Tickers: AET, ARTC, AUXL

    Insiders have information about a company which is not available to outside investors. On the other hand, institutional investors have a lot of resources at their disposal to better assess a stock, something which is not possible for retail investors. The companies listed below have witnessed heavy selling by institutional investors and insiders, which is a strong sell indicator.

    Aetna (NYSE: AET) is a diversified health care benefits company with more »

  • Is The Risk Worth The Large Potential Reward?

    By Mike Thiessen - April 29, 2013 | Tickers: ABBV, AUXL, LLY

    Auxilium Pharmaceuticals (NASDAQ: AUXL) stock has a lot of negative sentiment priced into the shares, maybe too much at this point. Often when the Street has bearish outlook on a stock, interest in it falls off and the shares overshoot fair value. This can create opportunities for investor.

    Auxilium is a biopharmaceutical company that develops and markets products to two specialized markets. The company currently markets Testim testosterone gel and more »

  • This Hedge Fund's Picks Have Returned 20% Two Straight Quarters

    By Meena Krishnamsetty - November 6, 2012 | Tickers: AUXL, CYBX, MRX, ONXX, VPHM

    We track over 400 funds and investors, and have calculated the value-weighted returns for all funds in the 1500 largest stocks, while compiling a list of the top performing funds for the first three quarters of 2012. The returns are based on the fund’s 13F long positions only, as we do not have access to their short positions.

    Palo Alto has done it again, finishing in the top five more »

  • Two Stocks Bucking the Selling

    By Declan Fallon - June 15, 2012 | Tickers: AUXL, CYBX, MDT

    Since the start of May, when sellers hit the market there is a sense of looking at it through the fingers of your hand so difficult is it to gauge how much damage they will do.  However, there are stocks - few and far between - which have tried to buck this trend.  Two stocks which have enjoyed above average buying are Auxilium Pharmaceuticals (NASDAQ: AUXL) and Cyberonics Inc (NASDAQ: CYBX).

    Auxilium more »